ClinicalTrials.gg

Program

QRX-3

Its studies are mostly in Acute Kidney Injury · Renal Insufficiency, Chronic · Diabetic Nephropathies, led by Ebima Clifford Okundaye.

Furthest: phase 3, since Mar 4, 20253 company-led studies, 2 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ebima Clifford Okundaye32 open or runningphase 3since Mar 4, 2025Mar 4, 2025Dec 30, 2026phase 3 · NCT07161843

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 4, 2025First study: phase 3 study in Renal Insufficiency, ChronicFirst studyNCT06866236 · 3,000 planned · United States
  2. Apr 10, 2025Phase 3 study in Acute Kidney InjuryNCT07161843 · 500 planned · United States
  3. Apr 21, 2025Phase 2 study in Diabetic NephropathiesNCT06948292 · 127 enrolled · United States

Ahead

  1. Dec 30, 2026Primary completion: phase 3 study in Acute Kidney InjuryNCT07161843

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06948292Diabetic Nephropathies · United States2CompletedAug 30, 2024127
NCT07161843Acute Kidney Injury · United States3Not yet recruitingDec 30, 2026500
NCT06866236Renal Insufficiency, Chronic · United States3Not yet recruitingOct 20263,000

How it is read

Names in the registry

  • “QRX-3”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
QRX-3 (Ebima Clifford Okundaye): development program | ClinicalTrials.gg